BioNTech, XPhyto, Valneva: 3 stocks for next week?

BioNTech: This share could turn around

The BioNTech share has attracted attention in recent weeks with price fluctuations - the value fell by 38% in one month. Currently, the share is preparing to turn upwards again from the low of last November. In line with the chart situation, good news has come to light for BioNTech. Together with Pfizer, the Company has developed a vaccine against shingles triggered by herpes viruses. Shingles mainly affects older people. A vaccine could become a big seller. At the same time, there are reports of a new mutant from France that is said to be genetically even more different from the original type of coronavirus.

Both pieces of news are positive for BioNTech: Since the Company can react flexibly to new challenges and already has the image of a Mercedes among vaccine manufacturers, the cash register should continue to ring for the Mainz-based Company. In addition, more and more new Corona variants indicate that BioNTech will also be responsible for the fourth and possibly fifth prick. The share could become exciting in the coming days.

XPhyto: Several irons in the fire

The situation is also interesting for XPhyto, a specialist in diagnostics and drug delivery. The Canadian Company has acquired several German companies in recent months and years and therefore has good business relations in Germany. Its flagship product is the Company's rapid PCR test, which promises PCR-quality results after just 25 minutes. In times when even vaccinated people are becoming increasingly infected and remain under the radar with mild symptoms, the sensitive PCR tests could be the key to greater safety. XPhyto wants to bring its products to customers primarily at airports. There, a rapid PCR test between landing and baggage claim could provide the highest level of security. In addition to corona tests, Xphyto also offers oral health tests.

Other areas of activity for the Company include innovative delivery forms, such as active ingredient patches. Studies suggest that certain active ingredients can be used better and more cost-effectively, thanks to alternative delivery forms. On the other hand, the Company's activities in the field of psychedelics are speculative: XPhyto wants to fight depression with mescaline and other substances. A few months ago, researchanalyst.com wrote about this in a research piece on XPhyto: "While this topic has not yet struck a chord with physicians and decision-makers in the healthcare sector in Germany, people in North America are more open-minded. With XPhyto's presence in both regions, the Company can advance this speculative business area within a constructive environment." XPhyto's stock remains highly speculative but should be on the minds of short-term investors, especially in the coming days. The share is well-positioned if the market swings back into pandemic mode.

Valneva: What are the authorities doing?

In recent weeks, Valneva's shares have also been heavily traded on the market. These days, the manufacturer of a vaccine candidate is likely to be looking eagerly to the European Medicines Agency (EMA). There, the French manufacturer's inactivated vaccine is currently being tested. However, it remains to be seen how long this review will last and whether the parallel studies, such as the use of the vaccine as a booster, can still have a positive effect during the current wave. The share price has almost halved from its high a few weeks ago. The stock is a hot potato.

Instead of relying on the authorities, investors would be better off betting on established players, such as BioNTech. Here, the conditions are good to take off with new vaccine variants and entirely new vaccines based on mRNA. XPhyto could be an insider tip. Here, three promising investment stories come together. However, the value is extremely speculative and is in a downward trend.